Skip to main content
. 2015 Jun 25;17(1):87. doi: 10.1186/s13058-015-0572-5

Table 1.

Univariate and multivariate analysis of elafin-positive cells in breast cancer patients

A. Univariate analysis, breast cancer (n = 793)
Factors Elafin negative (n = 311) Elafin positive (n = 482) p-value
Age of diagnosis, year 0.02
  Mean 55.5 53.5
  Median (range) 55 (26–86) 52 (25–87)
Stage <0.0001
  I 120 (38.7) 115 (24.0)
  IIA 128 (41.3) 241 (50.2)
  IIB 62 (20.0) 124 (25.8)
  Unknown 1 2
ER <0.0001
  Positive 266 (85.5) 280 (58.3)
  Negative 45 (14.5) 200 (41.7)
  Unknown 0 2
PR <0.0001
  Positive 218 (70.1) 236 (49.2)
  Negative 93 (29.9) 244 (50.8)
  Unknown 0 2
HER-2 0.013
  Positive 42 (13.5) 98 (20.4)
  Negative 269 (86.5) 383 (79.6)
  Unknown 0 1
Grade <0.0001
  I 41 (14.2) 31 (6.8)
  II 186 (64.6) 197 (43.5)
  III 61 (21.2) 225 (49.7)
  Unknown 23 29
Tumor subtype <0.0001
  Luminal A 185 (61.9) 158 (33.1)
  Luminal B 45 (15.1) 94 (19.8)
  Her2 positive 42 (14.0) 98 (20.7)
  Triple negative 27 (9.0) 125 (26.4)
  Unknown 12 7
Recurrence <0.0001
  No 250 (80.9) 298 (62.3)
  Yes 59 (19.1) 180 (37.7)
  Unknown 2 4
B. Multivariate Cox proportional hazards analysis of clinicopathologic variables’ influence on breast cancer RFS in whole cohort (n = 793)
Factor HR Se P 95% CI
Stage
  I referent
  IIA 1.67 0.31 0.005 1.17-2.39
  IIB 2.41 0.47 <0.0001 1.65-3.52
Age 0.98 0.01 <0.0001 0.97-0.99
Elafin Positive 1.94 0.3 <0.0001 1.44-2.62